No internet connection — showing the saved version of the page.

The Cooper Compan…

USUSD
← to the screener

The Cooper Companies, Inc (US:COO) — Ophthalmic Goods. Number of exchanges where the company shares trade: 5. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
coopercos.com
Investor relations
investor.coopercos.com/
Sector
Health Care · Ophthalmic Goods
Headquarters
SAN RAMON, United States
Management
Albert G. White
Employees
15 000
Founded
1958
IPO
1983-01-21
Shares outstanding
190.16 M as of 2026-09-03
Free float
188.77 M
Market cap
11.39 B USD
Insiders
0.63%
Institutions
111.92%
Industry (SIC)
Ophthalmic Goods
Legal form
XTIQ
ISIN
US2166484020
LEI
QJKMVPIGLH7530PCUE20
P/E
20.9
EPS
2.91 USD
|
1.39
Graham number
32.18 USD price 89% above
ROE
5.6%
Payout ratio
0%
FCF
678 M USD
Debt
2.54 B USD
3.5 y of FCF
Earnings, FCF and dividends paid — for the 12 months to 31.07.2026 (the company's latest report).
Net income
570 M USD 12 mo.
For the 12 months to 31.07.2026 (4 quarters)
Revenue4.24 B USD
− Expenses3.69 B USD
Gross profit2.79 B USD
Net income570 M USD
History by quarter
RevenueExpensesLoss
31.10.2023: Revenue 927 M · Expenses 791 M · Operating profit 136 M · Net income 84.5 M31.01.2024: Revenue 932 M · Expenses 779 M · Operating profit 153 M · Net income 81.2 M30.04.2024: Revenue 943 M · Expenses 781 M · Operating profit 162 M · Net income 88.9 M31.07.2024: Revenue 1.00 B · Expenses 810 M · Operating profit 193 M · Net income 105 M31.10.2024: Revenue 1.02 B · Expenses 820 M · Operating profit 198 M · Net income 118 M31.01.2025: Revenue 965 M · Expenses 783 M · Operating profit 182 M · Net income 104 M30.04.2025: Revenue 1.00 B · Expenses 818 M · Operating profit 185 M · Net income 87.7 M31.07.2025: Revenue 1.06 B · Expenses 885 M · Operating profit 176 M · Net income 98.3 M31.10.2025: Revenue 1.07 B · Expenses 925 M · Operating profit 140 M · Net income 84.6 M31.01.2026: Revenue 1.02 B · Expenses 811 M · Operating profit 213 M · Net income 131 M30.04.2026: Revenue 1.08 B · Expenses 1.11 B · Operating profit −31.0 M · Net income −77.9 M31.07.2026: Revenue 1.07 B · Expenses 844 M · Operating profit 222 M · Net income 433 M
10.202307.2026
Green above orange is profit (revenue − expenses); red below zero is a loss.
NAV
43.81 USD · P/NAV 1.39
Balance sheet date31.07.2026
Assets12.7 B USD
− Liabilities4.35 B USD
= Total equity8.33 B USD
− Non-controlling interests200 K USD
= NAV (equity of the company's shareholders)8.33 B USD
− Goodwill3.88 B USD
− Intangible assets1.45 B USD
= Tangible NAV3.01 B USD
Shares190 100 000
NAV per share43.81 USD
Tangible NAV per share15.81 USD
Share price (COO)60.7200 USD
P/NAV1.39
NAV history
Balance sheet dateNAVNAV per share
31.07.20268.33 B USD43.81 USD
30.04.20268.24 B USD42.27 USD
31.01.20268.36 B USD42.87 USD
31.10.20258.24 B USD42.06 USD
31.07.20258.35 B USD42.02 USD
30.04.20258.29 B USD41.54 USD
31.01.20258.13 B USD40.66 USD
31.10.20248.08 B USD40.50 USD
Description

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
common stock
US USA StocksCOO primaryUSD60.72 -1.87%common stock
LSE London Stock Exchange0I3I IOBUSD61.29 0.00%common stock
MI Borsa Italiana (Milan)1COO secondaryEUR56.99 +0.72%common stock
MX Mexican Stock ExchangeCOO secondaryMXN985 +0.00%common stock
XETRA XetraCP60 secondaryEUR56.96 +0.89%common stock
depositary receipt
SA B3 Sao PauloC1OO34BRL30.72 +0.89%depositary receipt

Price

Hover / tap a day — open, close, high and low prices

Dividends

Ex-datePaymentAmount%TypeTicker
2023-07-26—0.0300 USD0.0/0.0 %—LSE:0I3I

Top holders

HolderStakeSharesReport date
Blackrock Inc.7.9%15.03 M2026-06-30
Vanguard Capital Managem…6.71%12.76 M2026-06-30
State Street Corporation4.68%8.89 M2026-06-30
Vanguard Portfolio Manag…4.56%8.67 M2026-06-30
T. Rowe Price Investment…3.91%7.43 M2026-06-30
Browning West Lp3.78%7.2 M2026-06-30
VANGUARD INDEX FUNDS-Van…3.26%6.19 M2026-06-30
Price (T.Rowe) Associate…2.93%5.58 M2026-06-30
Kayne Anderson Rudnick I…2.86%5.43 M2026-06-30
Geode Capital Management…2.82%5.36 M2026-06-30
Franklin Resources, Inc.2.68%5.1 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.66%5.06 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.35%4.47 M2026-06-30
T. Rowe Price Mid-Cap Gr…2.04%3.88 M2026-06-30
VANGUARD INDEX FUNDS-Van…1.49%2.83 M2026-06-30
Invesco Exchange-Traded…1.47%2.79 M2026-08-31
T. Rowe Price Mid-Cap Va…1.45%2.76 M2026-06-30
iShares Trust-iShares Co…1.37%2.6 M2026-08-31
JANUS INVESTMENT FUND-Ja…1.33%2.52 M2026-06-30
Fidelity Concord Street…1.33%2.52 M2026-07-31
WEISS ROBERT S (Director…≈0.29%550 4592026-04-01
WHITE ALBERT G III (Chie…≈0.13%245 0722026-01-08
MCBRIDE DANIEL G (Chief…≈0.09%163 8482026-01-08
SHEFFIELD HOLLY R (Offic…≈0.02%43 2612026-01-08
JAY COLLEEN E (Director)≈0.02%39 9072026-04-01
KOZY WILLIAM A (Director…≈0.02%31 1492025-04-01
KURZIUS LAWRENCE ERIK (D…≈0.02%31 0992026-09-16
ANDREWS BRIAN G (Chief F…≈0.02%30 7282026-01-08
WARNER GERARD H, III (Of…≈0.01%23 8522026-01-08
ROSEBROUGH WALTER M JR (…——2026-09-14